Edition:
United Kingdom

Becton Dickinson and Co (BDX.N)

BDX.N on New York Stock Exchange

250.84USD
19 Jul 2019
Change (% chg)

$-2.99 (-1.18%)
Prev Close
$253.83
Open
$254.12
Day's High
$254.12
Day's Low
$250.71
Volume
201,215
Avg. Vol
287,558
52-wk High
$265.87
52-wk Low
$208.67

Latest Key Developments (Source: Significant Developments)

FDA Says Becton Dickinson & Company Recalls SmartSite Syringe Administration Set Due To Risk Of Leaks
Monday, 1 Jul 2019 

July 1 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS BECTON DICKINSON & COMPANY RECALLS SMARTSITE SYRINGE ADMINISTRATION SET DUE TO RISK OF LEAKS.U.S. FDA SAYS HAS IDENTIFIED BECTON DICKINSON'S RECALL OF THE SMARTSITE SYRINGE ADMINISTRATION SET AS A CLASS I RECALL.U.S. FDA SAYS BECTON DICKINSON RECALLED 2,900 SMARTSITE SYRINGE ADMINISTRATION SETS IN THE U.S; BECTON DICKINSON INITIATED RECALL ON FEB 22, 2019.U.S. FDA SAYS BECTON DICKINSON HAS NOT RECEIVED ANY REPORTS OF SERIOUS INJURY OR DEATH DUE TO MALFUNCTION OF SMARTSITE SYRINGE ADMINISTRATION SET.  Full Article

BD Gets FDA Approval For First Venous Stent
Thursday, 14 Mar 2019 

March 14 (Reuters) - Becton Dickinson and Co ::BD RECEIVES U.S. FDA APPROVAL FOR FIRST VENOUS STENT TO TREAT ILIOFEMORAL VENOUS OCCLUSIVE DISEASE.BECTON DICKINSON AND CO - VENOVO VENOUS STENT PROVEN SAFE AND EFFECTIVE IN ILIAC AND FEMORAL VEINS.  Full Article

UK Regulator Says No Safety Concerns On Recall Of C.R. Bard's Urogynaecological Mesh
Thursday, 7 Mar 2019 

March 7 (Reuters) - UK's Medicines And Healthcare Products Regulatory Agency: :UK'S MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY - MEDICAL DEVICE ALERT ISSUED FOR UROGYNAECOLOGICAL MESH MANUFACTURED BY C.R. BARD.UK'S MEDICINES & HEALTHCARE PRODUCTS REGULATORY AGENCY - ALERT ISSUED ON C.R. BARD REMOVING VAGINAL MESH FOR SUI, PELVIC ORGAN PROLAPSE FROM MARKET.UK'S MEDICINES & HEALTHCARE PRODUCTS REGULATORY AGENCY - NO SPECIFIC SAFETY CONCERNS ASSOCIATED WITH RECALL OF C.R. BARD'S UROGYNAECOLOGICAL MESH.  Full Article

Becton Dickinson and Co Sees Q1 EPS Of $2.05
Thursday, 17 Jan 2019 

Jan 17 (Reuters) - Becton Dickinson and Co ::BD ANNOUNCES PRELIMINARY RESULTS FOR 2019 FIRST FISCAL QUARTER; REAFFIRMS FISCAL 2019 GUIDANCE.SEES Q1 EARNINGS PER SHARE ABOUT $2.05.Q1 PRELIMINARY EARNINGS PER SHARE $2.05.Q1 EARNINGS PER SHARE ESTIMATE $2.61 -- REFINITIV IBES DATA.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $12.05 TO $12.15.Q1 PRELIMINARY ADJUSTED EARNINGS PER SHARE $2.70.SEES FY 2019 REVENUE UP 8.5 TO 9.5 PERCENT.Q1 REVENUE $4.16 BILLION VERSUS REFINITIV IBES ESTIMATE OF $4.11 BILLION.SEES Q1 2019 REVENUE $4.16 BILLION.REAFFIRMS PREVIOUSLY ISSUED FISCAL YEAR 2019 REVENUE AND ADJUSTED DILUTED EPS GUIDANCE.Q1 EARNINGS PER SHARE VIEW $2.61, REVENUE VIEW $4.11 BILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $12.12, REVENUE VIEW $17.43 BILLION -- REFINITIV IBES DATA.  Full Article

Becton, Dickinson And Co Sets Quarterly Dividend Of $0.77 Per Share
Monday, 19 Nov 2018 

Nov 19 (Reuters) - Becton Dickinson and Co ::SETS QUARTERLY DIVIDEND OF $0.77PER SHARE.SAYS DIVIDEND REPRESENTS INCREASE OF 2.7 PERCENT FROM PREVIOUS QUARTER.  Full Article

Becton Dickinson Announces Clinical Trial Data For The Lutonix 014 DCB
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Becton Dickinson and Co ::BD ANNOUNCES CLINICAL TRIAL DATA FOR THE LUTONIX® 014 DRUG-COATED BALLOON BELOW-THE-KNEE IDE TRIAL.BECTON DICKINSON - STUDY'S PRIMARY SAFETY ENDPOINT WAS MET SHOWING STATISTICALLY SIGNIFICANT SAFETY EQUIVALENCE BETWEEN LUTONIX 014 DCB & STANDARD PTA CATHETER.  Full Article

Becton Dickinson Says Entered 364-Day Term Loan Agreement
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - Becton Dickinson and Co ::BECTON DICKINSON AND CO SAYS ON SEPTEMBER 6, CO ENTERED 364-DAY TERM LOAN AGREEMENT - SEC FILING.BECTON DICKINSON AND CO - TERM LOAN AGREEMENT IS A SENIOR UNSECURED TERM LOAN FACILITY THAT PROVIDED CO WITH $750 MILLION OF TERM LOANS.BECTON DICKINSON AND CO - BORROWINGS UNDER TERM LOAN FACILITY WERE USED TO PARTIALLY REFINANCE 3 YEAR TERM LOAN AGREEMENT, DATED AS OF MAY 12, 2017.  Full Article

BD Statement On Divestiture Of Advanced Bioprocessing Business
Friday, 7 Sep 2018 

Sept 7 (Reuters) - Becton Dickinson and Co ::BD STATEMENT ON DIVESTITURE OF ADVANCED BIOPROCESSING BUSINESS.BECTON DICKINSON AND CO - EXPECTS TO RECORD A TAX GAIN ON TRANSACTION AT TIME OF CLOSING.BECTON DICKINSON - FOR FISCAL 2018, BD ESTIMATES CONTRIBUTION FROM ADVANCED BIOPROCESSING BUSINESS TO EPS OF ABOUT $0.13 TO $0.15 ON A FY BASIS.  Full Article

Thermo Fisher Scientific To Acquire Advanced Bioprocessing Business From BD
Friday, 7 Sep 2018 

Sept 7 (Reuters) - Thermo Fisher Scientific Inc ::THERMO FISHER SCIENTIFIC TO ACQUIRE ADVANCED BIOPROCESSING BUSINESS FROM BD.THERMO FISHER SCIENTIFIC INC - BD'S ADVANCED BIOPROCESSING BUSINESS WILL BE INTEGRATED INTO THERMO FISHER'S LIFE SCIENCES SOLUTIONS SEGMENT.  Full Article

Becton Dickinson and Co Posts Q3 Adj Earnings $2.91/Shr
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Becton Dickinson and Co ::BD ANNOUNCES RESULTS FOR 2018 THIRD FISCAL QUARTER; RAISES FISCAL 2018 REVENUE GUIDANCE.Q3 EARNINGS PER SHARE $2.03.Q3 REVENUE $4.278 BILLION VERSUS I/B/E/S VIEW $4.24 BILLION.Q3 EARNINGS PER SHARE VIEW $2.86 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $10.95 TO $11.05.Q3 ADJUSTED EARNINGS PER SHARE $2.91.RAISING FULL FISCAL YEAR 2018 REVENUE GUIDANCE, EXPECTS GROWTH TO EXCEED 31.5 PERCENT ON A REPORTED BASIS.BECTON DICKINSON - FOR FY18, ON A COMPARABLE, CURRENCY-NEUTRAL BASIS, CO IS ALSO RAISING ITS REVENUE GUIDANCE, NOW EXPECTS GROWTH TO EXCEED 5.5 PERCENT.REAFFIRMS ACQUISITION OF C.R. BARD EXPECTED TO BE ACCRETIVE TO ADJUSTED. EARNINGS PER SHARE ON A HIGH-SINGLE DIGIT BASIS IN FISCAL 2019.  Full Article

BRIEF-Enzo Biochem Says CO Considering All Available Options For Challenging Federal Circuit Panel's Decision

* ENZO BIOCHEM - U.S. COURT OF APPEALS ISSUED OPINION AFFIRMING LOWER COURT JUDGMENTS OF PATENT INVALIDITY FOR U.S. PATENT NOS. 6,992,180 & 8,097,405